Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.72 |
| ▸ | CA2 | P00918 | 9/20 | 0.72 |
| ▸ | CA1 | P00915 | 8/20 | 0.72 |
| ▸ | CA12 | O43570 | 8/20 | 0.72 |
| ▸ | CA9 | Q16790 | 8/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.72 |
| ▸ | CA4 | P22748 | 3/20 | 0.72 |
| ▸ | CA7 | P43166 | 3/20 | 0.72 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.72 |
| ▸ | CA3 | P07451 | 2/20 | 0.72 |
| ▸ | CA6 | P23280 | 2/20 | 0.72 |
| ▸ | CA5A | P35218 | 2/20 | 0.72 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.72 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170420 | 0.85 | PTGS2 (0.82) | PTGS2CA2CA1CA12CA9 | |
| SCHEMBL28635457 | 0.84 | PTGS2 (0.69) | PTGS2CA2CA1CA12CA9 | |
| Valdecoxib SCHEMBL3853130 | 0.84 | PTGS2 (1.00) | PTGS2CA2CA1CA12CA9 | |
| Valdecoxib SCHEMBL3356 | 0.84 | PTGS2 (1.00) | PTGS2CA2CA1CA12CA9 | |
| SCHEMBL6168344 | 0.84 | PTGS2 (1.00) | PTGS2CA2CA1CA12CA9 | |
| SCHEMBL14267686 | 0.83 | PTGS2 (1.00) | PTGS2CA2CA1CA12CA9 | |
| SCHEMBL4888365 | 0.83 | PTGS2 (0.78) | PTGS2CA2CA1CA12CA9 | |
| SCHEMBL7799111 | 0.83 | PTGS2 (0.78) | PTGS2CA2CA1CA12CA9 | |
| Valdecoxib SCHEMBL5999213 | 0.83 | PTGS2 (0.97) | PTGS2CA2CA1CA12CA9 | |
| Valdecoxib SCHEMBL6601157 | 0.83 | PTGS2 (0.97) | PTGS2CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010055565-A1 | Method of detecting cyclooxygenase-2 | G.D. SEARLE & CO. (US) | 2001-12-27 | — | — | US | claimed |
| US-6045773-A | Method of detecting cyclooxygenase-2 | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | claimed |
| EP-0859642-A2 | METHOD OF DETECTING CYCLOOXYGENASE-2 | G.D. SEARLE & CO. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997014679-A2 | METHOD OF DETECTING CYCLOOXYGENASE-2 | G.D. SEARLE & CO. (US) | 1997-04-24 | — | — | WO | claimed |
| US-20010055565-A1 | Method of detecting cyclooxygenase-2 | G.D. SEARLE & CO. (US) | 2001-12-27 | — | — | US | disclosed |
| US-6045773-A | Method of detecting cyclooxygenase-2 | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0859642-A2 | METHOD OF DETECTING CYCLOOXYGENASE-2 | G.D. SEARLE & CO. (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997014679-A2 | METHOD OF DETECTING CYCLOOXYGENASE-2 | G.D. SEARLE & CO. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010055565-A1 | Method of detecting cyclooxygenase-2 | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885CA2 221/4885CA1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.